Skip to main content

Zymeworks Inc.

ZYME
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001937653

No open-market purchases or sales by Zymeworks Inc. insiders were filed in the last 90 days; 202 institutions reported holding it in 13F filings for Q2 2026, worth $1.79B in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Zymeworks Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of ZYME: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders11491−23
Shares47.7M47.8M+73.5K (+0.2%)
Value$253.3M$293.7M+$40.5M (+16.0%)

New holders (11)

Institutions that held Zymeworks Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to ZYME in Q3 2022
InstitutionSharesValue% of portfolio
Strategic Wealth Advisors Group, LLC296,375$1.82M0.08%
Point72 Asset Management, L.P.244,000$1.50M0.01%
Velan Capital Investment Management LP234,902$1.45M1.69%
Millennium Management LLC192,628$1.19M0.00%
Ergoteles LLC59,457$366.0K0.01%
Renaissance Technologies LLC57,777$355.0K0.00%
Royal Bank of Canada33,882$208.0K0.00%
Y-Intercept (Hong Kong) Ltd25,374$156.1K0.02%
Thrivent Financial for Lutherans16,082$93.0K0.00%
ExodusPoint Capital Management, LP11,079$68.0K0.00%
The PNC Financial Services Group, Inc.178$1.00K0.00%

Sold out (34)

Institutions that held Zymeworks Inc. at the end of Q2 2022 and filed for Q3 2022 without it.